Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 9/20 | 0.76 |
| ▸ | PPARG | P37231 | 6/20 | 0.73 |
| ▸ | CTSS | P25774 | 2/20 | 0.58 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.53 |
| ▸ | KLK7 | P49862 | 2/20 | 0.49 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.49 |
| ▸ | PPARD | Q03181 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.47 |
| ▸ | CDC25B | P30305 | 2/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.47 |
| ▸ | CDC25A | P30304 | 1/20 | 0.47 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4995001 | 1.00 | PPARA (0.76) | PPARAPPARGCTSSCACNA1BKLK7 | |
| SCHEMBL12130757 | 0.94 | PPARA (0.85) | PPARAPPARGCTSSKLK7KLK5 | |
| SCHEMBL22390633 | 0.90 | PPARA (0.63) | PPARAPPARGCTSSCACNA1BPPARD | |
| SCHEMBL22390631 | 0.90 | PPARA (0.63) | PPARAPPARGCTSSCACNA1BPPARD | |
| SCHEMBL14058699 | 0.89 | PPARA (0.78) | PPARAPPARGCTSSKLK7KLK5 | |
| SCHEMBL14058698 | 0.89 | PPARA (0.78) | PPARAPPARGCTSSKLK7KLK5 | |
| SCHEMBL14123546 | 0.89 | PPARA (0.61) | PPARAPPARGCTSSCACNA1BKLK7 | |
| SCHEMBL828674 | 0.88 | PPARA (0.90) | PPARAPPARGCTSSKLK7KLK5 | |
| SCHEMBL1132901 | 0.88 | PPARA (0.90) | PPARAPPARGCTSSKLK7KLK5 | |
| SCHEMBL17051 | 0.88 | PPARA (0.90) | PPARAPPARGCTSSKLK7KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2852591-A1 | L-MALATE SALT OF 2, 7 - DIAZA - SPIRO [4.5]DEC- 7 - YLE DERIVATIVES AND CRYSTALLINE FORMS THEREOF AS GHRELIN RECEPTOR AGONISTS | Novartis AG (CH) | 2015-04-01 | — | — | EP | disclosed |
| US-20130331369-A1 | 3-Spirocyclic Piperidine Derivatives as Ghrelin Receptor Agonists | NOVARTIS AG (CH) | 2013-12-12 | — | — | US | disclosed |
| WO-2013164790-A1 | L-MALATE SALT OF 2, 7 - DIAZA - SPIRO [4.5 ] DEC- 7 - YLE DERIVATIVES AND CRYSTALLINE FORMS THEREOF AS GHRELIN RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2013-11-07 | — | — | WO | disclosed |
| US-20130296358-A1 | 3-SPIROCYCLIC PIPERIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | NOVARTIS PHARMACEUTICALS UK LIMITED (GB) | 2013-11-07 | — | — | US | disclosed |
| US-8546416-B2 | 3-spirocyclic piperidine derivatives as ghrelin receptor agonists | NOVARTIS AG (CH) | 2013-10-01 | — | — | US | disclosed |
| WO-2012164473-A1 | 3-SPIROCYCLIC PIPERIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-12-06 | — | — | WO | disclosed |
| US-20120302540-A1 | 3-SPIROCYCLIC PIPERIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | NOVARTIS PHARMACEUTICALS UK LIMITED (GB) | 2012-11-29 | — | — | US | disclosed |
| US-7396846-B2 | Growth hormone secretagogues | ELI LILLY AND COMPANY (US) | 2008-07-08 | — | — | US | disclosed |
| EP-1497316-B1 | GROWTH HORMONE SECRETAGOGUES | LILLY CO ELI (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20050240001-A1 | 2-(2-Amino-2-methylpropionylamino)-3-(2,6-difluoro-3-methylphenyl)methoxy propionic acid N-[5-(4-chlorophenyl)-3,3-dimethyl-1,1-dioxo-2,3-dihydroisothiazol-4-ylmethyl]-N-ethylamide; endogenous human growth hormone controller; non-peptidyl in nature, more metabolically stable | ELI LILLY AND COMPANY (US) | 2005-10-27 | — | — | US | disclosed |
| EP-1497316-A2 | GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003087070-A2 | GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331369-A1 | 3-Spirocyclic Piperidine Derivatives as Ghrelin Receptor Agonists | GIPR, GHSR, GLP1R | PPARA 93/4885PPARG 44/4885CTSS 2621/4885 |
| US-20130296358-A1 | 3-SPIROCYCLIC PIPERIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | GIPR, GHSR, GLP1R | PPARA 93/4885PPARG 44/4885CTSS 2621/4885 |
| US-20120302540-A1 | 3-SPIROCYCLIC PIPERIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | GIPR, GHSR, GLP1R | PPARA 93/4885PPARG 44/4885CTSS 2621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.